Mergers and acquisitions in biotechnology sector

Introduction

Mergers and acquisitions (M&A) in the biotechnology sector refer to business transactions through which biotechnology companies combine their operations, acquire other enterprises or obtain control over businesses engaged in pharmaceuticals, genetic engineering, medical research, diagnostics, vaccines, agricultural biotechnology and life sciences.

These transactions help companies expand research capabilities, acquire patents, access new technologies, enter international markets and strengthen their commercial position. For example, a pharmaceutical company may acquire a biotechnology start-up to obtain rights over an innovative drug, gene therapy platform or diagnostic technology.

However, biotechnology M&A transactions involve complex legal issues because their value often depends on intellectual property, clinical-trial results, regulatory approvals, biological materials, research data and specialised employees. Therefore, such transactions require careful legal, financial, scientific and regulatory examination.

Legal framework governing biotechnology M&A in India

Several Indian laws regulate mergers and acquisitions, depending on the structure of the transaction and the parties involved.

1. Companies Act, 2013

Sections 230–232 provide the framework for compromises, arrangements, mergers and amalgamations. The National Company Law Tribunal (NCLT) plays an important role in approving schemes of arrangement. The process generally involves disclosures, shareholder and creditor approvals where required, and consideration of statutory requirements.

Section 233 provides a simplified merger procedure for specified classes of companies, subject to statutory conditions.

2. Competition Act, 2002

The Competition Act regulates combinations that may cause an appreciable adverse effect on competition in India. Sections 5 and 6 deal with combinations and their regulation by the Competition Commission of India (CCI).

Biotechnology mergers may raise competition concerns where they combine companies holding significant market shares in vaccines, medicines, diagnostic technologies or essential research platforms. The applicable notification thresholds and exemptions must be examined at the time of the transaction.

3. SEBI regulations

Where listed biotechnology companies are involved, the Securities and Exchange Board of India (SEBI) regulations become relevant. The SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, govern specified acquisitions of shares and control in listed companies. Applicable disclosure and insider-trading requirements must also be considered.

4. Patents Act, 1970

Biotechnology companies frequently hold valuable patents relating to medicines, biological processes, diagnostic technologies and genetic inventions. During an acquisition, parties must verify patent ownership, validity, licensing arrangements and existing disputes.

Section 68 requires certain assignments, licences and other interests in patents to be in writing and duly executed. Section 69 concerns registration of assignments and other interests.

5. Biological Diversity Act, 2002

Where a transaction involves access to Indian biological resources or associated traditional knowledge, the parties must examine applicable access and benefit-sharing requirements. The 2023 amendments modified the regulatory framework, and the applicable obligations depend on the parties, activities, resources and statutory exemptions.

6. Foreign Exchange Management Act, 1999

Foreign investment in Indian biotechnology companies must comply with FEMA, applicable foreign investment policy and relevant RBI regulations. The sector-specific entry route and conditions depend on the nature of the business and the investment structure.

Importance of due diligence in biotechnology acquisitions

Due diligence is one of the most important stages of a biotechnology acquisition. Unlike ordinary commercial businesses, biotechnology companies may possess technologies that have not yet received regulatory approval or achieved commercial success.

The acquiring company should examine:

Intellectual property: Patent ownership, pending applications, licensing agreements and infringement disputes.

Research and development: Scientific validity, research records, clinical-trial results and development timelines.

Regulatory compliance: Approvals, licences, manufacturing permissions and regulatory correspondence.

Clinical-trial liabilities: Participant consent, adverse-event reporting, ethical approvals and compensation obligations.

Environmental compliance: Laboratory safety, hazardous waste management and biosafety permissions.

Employment matters: Researcher contracts, confidentiality obligations and employee invention ownership.

Financial liabilities: Pending litigation, contractual obligations, outstanding loans and contingent liabilities.

Failure to identify these risks may result in substantial financial losses after the acquisition.

Intellectual property and technology transfer

Intellectual property is often the most valuable asset in biotechnology M&A. A company may acquire another business primarily to obtain ownership or commercial rights over patents, proprietary research platforms, manufacturing processes and biological technologies.

The acquisition agreement should clearly specify whether intellectual property is transferred through an asset purchase, share purchase, merger or separate licensing arrangement.

Particular attention should be given to jointly developed inventions, university research agreements, government-funded research and third-party licences. An acquisition cannot automatically eliminate contractual restrictions or third-party rights attached to intellectual property.

Competition and public interest concerns

Biotechnology mergers can improve innovation by combining scientific expertise and research resources. However, they may also reduce competition if dominant companies acquire smaller firms possessing important technologies or promising drug candidates.

The CCI may examine whether a transaction creates or strengthens market power, restricts access to essential technologies or reduces incentives for independent research.

In pharmaceutical and biotechnology markets, competition assessment may require examination of current products as well as pipeline products that could become future competitors.

Relevant judicial decisions

1. ArcelorMittal India Private Limited v. Satish Kumar Gupta (2018)

The Supreme Court examined the statutory framework governing corporate resolution under the Insolvency and Bankruptcy Code, 2016. Although it was not a biotechnology acquisition case, it is relevant to corporate acquisitions involving financially distressed biotechnology businesses because it explains the importance of statutory eligibility and compliance in corporate restructuring.

2. Vodafone International Holdings B.V. v. Union of India (2012)

The Supreme Court considered the taxation of an offshore transaction involving the indirect transfer of Indian assets. The judgment is relevant to cross-border biotechnology acquisitions because international share transfers may raise complex questions concerning Indian tax jurisdiction and transaction structuring. Subsequent legislative developments must also be considered.

3. Competition Commission of India v. Thomas Cook (India) Ltd. (2018)

The Supreme Court considered competition-law issues arising from corporate restructuring and the CCI's jurisdiction. The decision is relevant to understanding the regulatory treatment of combinations and restructuring transactions, including those involving biotechnology enterprises.

4. Excel Crop Care Ltd. v. Competition Commission of India (2017)

The Supreme Court examined competition-law principles and the imposition of penalties under the Competition Act. Although the dispute concerned anti-competitive conduct rather than a merger, its discussion of competition principles is relevant to biotechnology companies whose acquisitions or subsequent commercial arrangements may affect market competition.

Challenges and safeguards

Biotechnology M&A transactions face several challenges, including uncertain clinical outcomes, patent disputes, regulatory delays, high research expenditure and differences between national regulatory systems.

To reduce these risks, parties should conduct independent scientific and legal due diligence, obtain necessary regulatory approvals, verify ownership of research assets and include appropriate representations, warranties and indemnity provisions in transaction documents.

Where appropriate, agreements may also include milestone-based payments, escrow arrangements and conditions precedent linked to regulatory approvals or intellectual property transfers.

Conclusion

Mergers and acquisitions play an important role in the growth of the biotechnology sector by facilitating investment, technology transfer, research expansion and commercial development. In India, these transactions are governed by the Companies Act, 2013, Competition Act, 2002, Patents Act, 1970, FEMA and other applicable regulatory laws. Judicial decisions concerning corporate restructuring, taxation and competition provide important legal principles for structuring such transactions. Ultimately, successful biotechnology M&A requires careful due diligence, protection of intellectual property, regulatory compliance and consideration of competition and public-interest concerns.